09:50 AM EST - Theralase Technologies Inc. : Has filed an Investigational Testing Authorization with Health Canada for approval to use its patent pending TLC-3200 Photo Dynamic Therapy Laser System and TLC-34XX Dosimetry Fibre Optic Cage technology, in conjunction with its Clinical Trial Application approved lead PDC, TLD-1433, in a Phase Ib clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer. Theralase Technologies Inc.
shares V.TLT are trading up $0.02 at $0.43.
